Depomed soars after royalty, milestone deal with PDL

|About: Depomed Inc. (DEPO)|By:, SA News Editor

Investors appear to be cheering Depomed's (DEPO) move to sell diabetes royalty and milestone rights to PDL BioPharma (PDLI).

DEPO +13% premarket

More on the deal here